Market Recap Check: Janux Therapeutics Inc (JANX)’s Positive Finish at 55.95, Up/Down 3.21

Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The price of Janux Therapeutics Inc (NASDAQ: JANX) closed at $55.95 in the last session, up 3.21% from day before closing price of $54.21. In other words, the price has increased by $3.21 from its previous closing price. On the day, 0.53 million shares were traded. JANX stock price reached its highest trading level at $56.55 during the session, while it also had its lowest trading level at $54.14.

Ratios:

We take a closer look at JANX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 57.34 and its Current Ratio is at 57.34. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, UBS on October 24, 2024, initiated with a Buy rating and assigned the stock a target price of $69.

On September 06, 2024, Stifel started tracking the stock assigning a Buy rating and target price of $70.

On May 30, 2024, Scotiabank started tracking the stock assigning a Sector Perform rating and target price of $47.Scotiabank initiated its Sector Perform rating on May 30, 2024, with a $47 target price.

Insider Transactions:

An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Oct 28 ’24 when Campbell David Alan sold 25,000 shares for $53.54 per share. The transaction valued at 1,338,559 led to the insider holds 282,054 shares of the business.

Reardon Tighe bought 15,122 shares of JANX for $807,666 on Oct 28 ’24. On Oct 28 ’24, another insider, Lichter Jay, who serves as the FORMER DIRECTOR of the company, bought 3,419 shares for $53.51 each.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, JANX now has a Market Capitalization of 2918603776 and an Enterprise Value of 2296002816. For the stock, the TTM Price-to-Sale (P/S) ratio is 192.90 while its Price-to-Book (P/B) ratio in mrq is 4.44. Its current Enterprise Value per Revenue stands at 151.782 whereas that against EBITDA is -35.951.

Stock Price History:

Over the past 52 weeks, JANX has reached a high of $65.60, while it has fallen to a 52-week low of $5.65. The 50-Day Moving Average of the stock is 17.35%, while the 200-Day Moving Average is calculated to be 38.97%.

Shares Statistics:

According to the various share statistics, JANX traded on average about 592.18K shares per day over the past 3-months and 683710 shares per day over the past 10 days. A total of 46.25M shares are outstanding, with a floating share count of 41.24M. Insiders hold about 20.95% of the company’s shares, while institutions hold 85.46% stake in the company. Shares short for JANX as of 1728950400 were 4332266 with a Short Ratio of 7.32, compared to 1726185600 on 3305621. Therefore, it implies a Short% of Shares Outstanding of 4332266 and a Short% of Float of 16.420001.

Most Popular